

NEBRASKA MEDICAID AD HOC FEE SCHEDULE

**This fee schedule is subject to change, as further Center of Medicare & Medicaid's (CMS) guidance occurs.
The updates in this version are reflected in red.**

COVID-19 CODES

CODE	MOD	DESCRIPTION	PA	COMMENTS	COPAY	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS THROUGH TO 3/14/2021	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS ON OR AFTER 3/15/2021
0034A		JANSEN COVID-19 VACCINE ADMINISTRATION - BOOSTER		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 11/2/2021
0051A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - First dose					\$36.94 Effective 12/27/2021
0052A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - Second dose					\$36.94 Effective 12/27/2021
0053A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - Third dose					\$36.94 Effective 12/27/2021
0054A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - Booster					\$36.94 Effective 12/27/2021
0071A		Pfizer-BioNTech Covid-19 Pediatric Vaccine - Administration - First dose		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 11/2/2021
0072A		Pfizer-BioNTech Covid-19 Pediatric Vaccine - Administration - Second dose		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 11/2/2021
0073A		IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE)					\$36.94 Effective 1/4/2022
0074A		Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) Administration Booster-ADM SARSCOV2 10MCG TRS-SUCRB					\$36.94 Effective 5/17/2022
0094A		MODERNA-ADM SARSCOV2 50MCG/0.5 MLBST					\$36.94 Effective 3/29/2022
0004A		Pfizer-BioNTech Covid-19 Vaccine Administration - Booster		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 9/22/2021
0064A		Moderna Covid-19 Vaccine (Low Dose) Administration - Booster		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 10/20/2021
0003A		PFIZER BIONTECH COVID-19 ADM SARSCOV2 30MCG/0.3ML 3RD DOSE		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 8/12/2021
0013A		MODERNA COVID-19 ADM SARSCOV2 100MCG/0.5ML 3RD DOSE		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 8/12/2021
M0201		COVID-19 VACCINE ADMINISTRATION INSIDE A PATIENT'S HOME		RATE CHANGE \$33.05 Effective 1/1/2022			\$32.50 Effective 8/6/2021
M0220		INJECTION, TIXAGENIVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS; INJECTION AND ADMINISTRATION MONITORING.					\$135.31 Effective 12/8/2021
M0221		INJECTION, TIXAGENIVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS; INJECTION AND ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE					\$225.36 Effective 12/8/2021
M0222		INTRAVENOUS INJECTION, BEBTELOVIMAB. INCLUDES INJECTION AND POST ADMINISTRATION MONITORING					\$350.50 Effective 2/11/2022
M0223		INTRAVENOUS INJECTION, BEBTELOVIMAB. INCLUDES INJECTION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE; THIS INCLUDES A BENEFICIARY'S HOME THAT HAS BEEN MADE PROVIDER-BASED TO THE HOSPITAL DURING THE COVID-19 PUBLIC HEALTH EMERGENCY					\$550.50 Effective 2/11/2022

						MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS THROUGH TO 3/14/2021	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS ON OR AFTER 3/15/2021
CODE	MOD	DESCRIPTION	PA	COMMENTS	COPAY		
Q0221		INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40kg) WITH NO KNOWN SARS-COV-2 EXPOSURE, WHO EITHER HAVE MODERATE TO SEVERELY COMPROMISED IMMUNE SYSTEMS OR FOR WHOM VACCINATION WITH ANY AVAILABLE COVID-19 VACCINE IS NOT RECOMMENDED DUE TO A HISTORY OF SEVERE ADVERSE REACTION TO A COVID-19 VACCINE(S) AND/OR COVID-19 VACCINE COMPONENT(S) 600mg					Not covered while federally supplied Effective 2/24/2022
Q0222		INJECTION, BEBTELOVIAMAB, 175MG					Not covered while federally supplied Effective 2/11/2022
M0240		INTRAVENOUS INFUSION OR SUBCUTANEOUS INJECTION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION OR INJECTION, AND POST ADMINISTRATION MONITORING, SUBSEQUENT REPEAT DOSES.		RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 7/30/2021
M0241		INTRAVENOUS INFUSION OR SUBCUTANEOUS INJECTION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION OR INJECTION, AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE, SUBSEQUENT REPEAT DOSES.		RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 7/30/2021
M0244		INTRAVENOUS INFUSION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE, SUBSEQUENT REPEAT DOSES.		RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 5/6/2021
M0246		INTRAVENOUS INFUSION, BAMLANIVIMAB AND ETESEVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE, SUBSEQUENT REPEAT DOSES.		RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 5/6/2021
M0247		INTRAVENOUS INFUSION, SOTROVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING		RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 5/26/2021
M0248		INTRAVENOUS INFUSION, SOTROVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE		RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 5/26/2021
M0249		INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS.. 1ST DOSE		RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 6/24/2021
M0250		INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS.. 2nd Dose		RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 6/24/2021
Q0247		INJECTION, SOTROVIMAB, 500mg					\$2,394.00 Effective 5/26/2021
Q0249		INJECTION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS.. WITH COVID-19..ECMO ONLY 1 MG					\$6.57 Effective 6/24/2021
D0606		MOLECULAR TESTING FOR A PUBLIC HEALTH RELATED PATHOGEN, INCLUDING CORONA VIRUS					\$51.31
D1701		PFIZER 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
D1702		PFIZER 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
D1703		MODERNA 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
D1704		MODERNA 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
D1707		JANSSEN SINGLE DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT					\$37.25
0031A		JANSSEN SINGLE DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT		RATE CHANGE \$36.94 Effective 1/1/2022		\$28.39	\$37.25
87426	QW	INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE, (EG, ENZYME IMMUNOASSAY, ENZYME-LINKED IMMUNOSORBENT ASSAY,		COVID EMERGENCY PERIOD		\$35.33	
87428	QW	INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE, (EG, ENZYME IMMUNOASSAY ENZYME-LINKED, IMMUNOSORBENT ASSAY, FLUORESC		COVID EMERGENCY PERIOD		\$63.59	\$30.94 EFFECTIVE 1/1/2022
87635	QW	AMPLIFIED DNA OR RNA PROBE DETECTION OF SARS CORONORIVUS		COVID EMERGENCY PERIOD		\$51.31	
M0243		INTRAVENOUS INFUSION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION AND POST ADMINISTRATION MONITORING		RATE CHANGE \$404.92 Effective 12/08/2021		\$309.60	\$404.78 Effective 5/6/2021

						MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS THROUGH TO 3/14/2021	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS ON OR AFTER 3/15/2021
CODE	MOD	DESCRIPTION	PA	COMMENTS	COPAY		
M0245		INTRAVENOUS INFUSION, BAMLANIVIMAB AND ETESEVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING		RATE CHANGE \$404.92 Effective 12/08/2021		\$309.60	\$404.78 Effective 5/6/2021
C9803		HOSPITAL OUTPATIENT CLINIC VISIT SPECIMEN COLLECTION FOR (SARS-COV-2) (COVID-19), ANY SPECIMEN SOURCE		COVID EMERGENCY PERIOD		\$23.00	
G2023		SPECIMEN COLLECTION FOR COVID-19, ANY SPECIMEN SOURCE		COVID EMERGENCY PERIOD		\$23.46	
G2024		SPECIMEN COLLECTION FOR COVID-19, FROM AN INDIVIDUAL IN A SNF OR LABORATORY ON BEHALF OF A HOME HEALTH AGENCY, ANY SPECIMEN SOURCE		COVID EMERGENCY PERIOD		\$25.46	
U0001		CDC 2019 NOVEL CORONAVIRUS (2019-NCOV) REAL-TIME RT-PCR DIAGNOSTIC PANEL		COVID EMERGENCY PERIOD		\$35.92	
U0002		NON-CDC SARS-COV-2/2019-NCOV (COVID-19)		COVID EMERGENCY PERIOD		\$51.31	
U0002	QW	NON-CDC SARS -COV-2/2019 -NCOV		COVID EMERGENCY PERIOD		\$51.31	
U0003		INFECTIOUS AGENT DETECTION BY DNA OR RNA;COVID-19,AMPLIFIED PROBE TECHNIQUE,HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R		COVID EMERGENCY PERIOD		\$100.00	\$75.00
U0004		COVID-19,ANY TECHNIQUE,MULTIPLE TYPES OR SUBTYPES,NON-CDC, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESRIBED BY CMS-2020-01-R		COVID EMERGENCY PERIOD		\$100.00	\$75.00
U0005		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$25.00	
0001A		PFIZER 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022		\$16.94	\$37.25
0002A		PFIZER 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022		\$28.39	\$37.25
0011A		MODERNA 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022		\$16.94	\$37.25
0012A		MODERNA 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022		\$28.39	\$37.25
0202U		INFECTIOUS DISEASE(BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION), PATHOGEN-SPECIFIC NUCLEIC ACID (DNA OR RNA), 22 TARGETS INCLUDING SEVERE A		COVID EMERGENCY PERIOD		\$298.60	\$416.78 EFFECTIVE 1/1/2021
0223U		INFECTIOUS DISEASE(BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION), PATHOGEN-SPECIFIC NUCLEIC ACID (DNA OR RNA), 22 TARGETS INCLUDING SEVERE A		COVID EMERGENCY PERIOD		\$298.60	\$416.78 EFFECTIVE 1/1/2021
0224U		ANTIBODY, SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2(SARS-COV-2) (CORONAVIRUS DISEASE YCOVID-19), INCLUDES TITER(S), WHEN PERFORMED (DO		COVID EMERGENCY PERIOD		\$42.13	
0225U		INFECTIOUS DISEASE (BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION) PATHOGEN-SPECIFIC DNA AND RNA, 21 TARGETS, INCLUDING SEVERE ACUTE RESPIRAT		COVID EMERGENCY PERIOD		\$298.60	\$416.78 EFFECTIVE 1/1/2021
0226U		SURROGATE VIRAL NEUTRALIZATION TEST (SVNT), SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCOVID-19), ELI		COVID EMERGENCY PERIOD		\$42.28	
0240U		INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION),PATHOGEN-SPECIFIC RNA, 3 TARGETS (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 YSARS		COVID EMERGENCY PERIOD		\$142.63	
0241U		INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION),PATHOGEN-SPECIFIC RNA, 4 TARGETS (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 YSARS		COVID EMERGENCY PERIOD		\$142.63	
86328		IMMUNOASSAY FOR INFECTIOUS AGENT ANTIBODY(IES), QUALITATIVE OR SEMIQUANTITATIVE, SINGLE STEP METHOD (EG, REAGENT STRIP); (SARS-COV-2)(COVID-19)		COVID EMERGENCY PERIOD		\$45.23	\$45.28 EFFECTIVE 1/1/2022
86408		SCREENING TEST FOR DETECTION OF SEVERE ACUTE RESPIRATORY SUNDROME CORONAVIRUS 2		COVID EMERGENCY PERIOD		\$42.13	
86409		MEASUREMENT OF NEUTRALIZING ANTIBODY TO SEVERE ACUTE RESPIRATORY SYNDROME CORONA		COVID EMERGENCY PERIOD		\$79.61	
86769		ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2(SARS-COV-2) (COVID-19)		COVID EMERGENCY PERIOD		\$42.13	

						MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS THROUGH TO 3/14/2021	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS ON OR AFTER 3/15/2021
CODE	MOD	DESCRIPTION	PA	COMMENTS	COPAY		
87301		INFECTIOUS AGENT ANTIGEN DETECTION BY ENZYME IMMUNOASSAY TECHNIQUE, QUALITATIVE OR SEMIQUANTITATIVE, MULTIPLE STEP METHOD; ADENO VIRUS		COVID EMERGENCY PERIOD		\$11.98	
87426		INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE,(EG, ENZYME IMMUNOASSAY YEIA , ENZYME-LINKED IMMUNOSORBENT ASSAY YELISA , IMMUNOCH		COVID EMERGENCY PERIOD		\$35.33	
87428		INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE,(EG, ENZYME IMMUNOASSAY YEIA , ENZYME-LINKED IMMUNOSORBENT ASSAY YELISA , FLUORESC		COVID EMERGENCY PERIOD		\$63.59	\$30.94 EFFECTIVE 1/1/2022
87635		DETECTION OF SARS-COV-2 AND ANY PAN-CORONAVIRUS TYPES OR SUBTYPES;INFECTIOUS AGENT DETECTION BY NUCLEIC ACID(DNA OR RNA; SEVERE ACUTE RESPIRATOR		COVID EMERGENCY PERIOD		\$51.31	
87636		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$142.63	
87637		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$142.63	
87811		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$41.38	